Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Micawber who wrote (1759)	9/29/2000 9:15:58 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Brian, You aren't going to get any argument from me on CLTR. I own it and have added recently. I personally don't believe it is that much of a crapshoot. The price can be partly explained by the credibility they lost over their BLA "re-formatting." I believe the drug works and will get approved. How widely and rapidly it will be adopted is less clear - the radioactivity is an issue here, as are the manufacturing costs and difficulties. There are other companies with approved drugs that have smaller market caps - for example SANG and KOSP. I'll follow up with a post giving the current market caps of the biotechs in my list - as always, I'm likely missing a few. There are about 300 pharmas and biotechs on my list with market caps in excess of $10 million. Peter